Indian pharmaceutical companies waiting for the launch of the updated relaxed medicine registration procedure in Ukraine for medicines registered in countries with tough regulatory policies to bring new medicines to the Ukrainian market, President of Indian Pharmaceutical Manufacturers’ Association in Ukraine (IPMA) Dr. Ramanan Menon has told Interfax-Ukraine.
“The decision to relax the registration of these medicines is positive for Indian manufacturers, but primarily for Ukrainian patients. When this system is fully operational, I think many Indian pharmaceutical companies will bring new modern medicines to the Ukrainian market,” he told Interfax-Ukraine.
Dr. Menon said that the procedure allows bringing not just new medicines to the Ukrainian pharmaceutical market, but those which effectiveness, safety and quality are confirmed by the most stringent regulatory authorities in the world.
“In India, there are a lot of plants owned by multinational companies that have all the certificates recognized in the world. I think that the relaxed registration will allow us to bring the most effective medicines to the Ukrainian market,” he said.
Dr. Menon said that the high quality and efficiency of the products of Indian pharmaceutical plants with their relatively low cost has long been appreciated by international organizations that are purchasing medicines on a global scale, including the UN family organizations – UNDP and UNICEF. These international organizations purchase medicines directly from manufacturers.
The head of IPMA recalled that Indian pharmaceutical companies are the winners of a significant part of tenders that are held by international organizations to buy medicines using funds from the national budget of Ukraine.
“Now the number of distributors in budget procurement has decreased. International organizations procure the medicines and Indian medicines have a certain share,” he said, adding that Indian pharmacies often cooperate with the world’s leading manufacturers of innovative drugs.
In particular, more than 80% of antiretroviral drugs used globally to fight AIDS are produced by Indian pharmaceutical companies. In particular, the Medicines Patent Pool (a patent organization funded by UN) signed six sub-licenses with Indian pharmaceutical companies Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs, which allowed them to create a new drug for AIDS – generic Tenofovir Alafenamide (TAF) for 112 developing countries.
